BRISTOL-MYERS SQUIBB COMPANY vs ELI LILLY AND COMPANY, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BMY and LLY diverge most: on revenue growth, BMY reads +3.1% and LLY reads +49.9%; on ev/ebitda, BMY reads 47.8 and LLY reads 550.3. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BMY | LLY |
|---|---|---|
| Price | $59.11 | $1178.18 |
| Market cap | $121.1B | $1.11T |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Mature |
| Implied growth (priced in) | — | +22.2% |
| P/E | 13.0 | 39.5 |
| P/B | 5.42 | 32.74 |
| P/S | 2.46 | 13.92 |
| EV/EBITDA | 47.8 | 550.3 |
| Revenue growth | +3.1% | +49.9% |
| Net margin | 18.9% | 33.5% |
| Return on equity | 41.6% | 78.8% |
| Return on assets | 10.6% | 18.8% |
| Return on invested capital | — | 1.4% |
| FCF yield | 9.4% | 1.6% |
| Dividend yield | 4.2% | 0.5% |
| Debt / equity | 1.97 | 1.62 |
| Current ratio | 1.53 | 1.35 |
| Altman Z (solvency) | 2.13 | 7.02 |
| Piotroski F (quality) | 8 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.